Preparations and Methods for Ameliorating or Reducing Presbyopia

ABSTRACT

This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.

RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.13/871,403, filed Apr. 26, 2013, which is a continuation of U.S.application Ser. No. 13/605,302, filed Sep. 6, 2012, which is acontinuation application of U.S. application Ser. No. 12/973,479, filedDec. 20, 2010, the entire contents of which is hereby incorporatedherein by reference. U.S. application Ser. No. 12/973,479 is acontinuation-in-part of U.S. patent application Ser. No. 12/785,734,filed on May 24, 2010, which claims the benefit of U.S. ProvisionalApplication No. 61/180,521, filed on May 22, 2009, and also claims thebenefit of U.S. Provisional Application No. 61/291,206, filed on Dec.30, 2009, the entire content of each of which is hereby incorporated byreference herein.

BACKGROUND

1. Technical Field Text

This application relates to the use of one or more parasympathomimeticdrugs or a cholinesterase inhibitor in combination with one or morealpha agonists or antagonist to create optically beneficial miosis to,for example, temporarily treat presbyopia.

2. Background Information

Presbyopia is typically age-related eye deterioration. Young, properlyfunctioning, eyes are able to see at near distances, an ability thatdeteriorates as one ages. Presbyopia normally develops as a person ages,and is associated with a natural progressive loss of accommodation. Apresbyopic eye loses the ability to rapidly and easily focus on objectsat near distances. Presbyopia progresses over the lifetime of anindividual, usually becoming noticeable after the age of 45 years. Bythe age of 65 years, the crystalline lens has often lost almost allelastic properties and has only limited ability to change shape.

Use of over the counter reading glasses is a very common way ofaddressing the vision problems associated with presbyopia. Readingglasses allow the eye to focus on near objects and maintain a clearimage. This approach is similar to that of treating hyperopia, orfarsightedness.

Many presbyopes are also prescribed bi-focal eyeglasses, where oneportion of the lens is corrected for distance vision and another portionof the lens is corrected for near vision. When peering down through thebifocals, the individual looks through the portion of the lens correctedfor near vision. When viewing distant objects, the individual lookshigher, through the portion of the bi-focals corrected for distancevision. Contact lenses and intra-ocular lenses (IOLs) have also beenused to treat presbyopia, for example, by relying on monovision (whereone eye is corrected for distance-vision, while the other eye iscorrected for near-vision) or bilateral correction with either bi-focalor multi-focal lenses. Laser ablation has also been used to treatpresbyopia. All these procedures seek to correct the problem for longterm purposes using drastic steps (surgery, laser ablation, etc) orrequire wearing corrective lenses.

Thus, there remains a need for new ways of ameliorating or reducingpresbyopia for patients that do not wish to undergo surgery (IOLs, laserablation, etc.) or use corrective glasses. For people who use correctivelenses, there remains a need to temporarily treat presbyopia without theuse of corrective lenses.

DESCRIPTION OF FIGURES

FIG. 1 shows change in visual acuity at 1 hr, 2 hrs, and 4 hrs afteradministration of 0.25% pilocarpine alone, 0.5% pilocarpine alone, 1.0%pilocarpine alone, 0.25% pilocarpine combined with 0.2% brimonidine,0.5%, pilocarpine combined with 0.2% brimonidine, or 1.0% pilocarpinecombined with 0.2% brimonidine

FIG. 2 shows the average change in visual acuity at 1, 2, 4, 8, and 10hours after administration for the active drug and placebo arms. Thesolid squares represent the average change in visual acuity for theactive drug arm whereas the solid triangles represent the average changein visual acuity for the placebo arm.

BRIEF SUMMARY

This application relates to a pharmaceutical preparation comprising oneor more parasympathomimetic drugs or cholinesterase inhibitors and oneor more alpha agonists or antagonists. In one embodiment, an ophthalmictopical preparation is provided, comprising a therapeutically effectiveamount of one or more parasympathomimetic drugs or one or morecholinesterase inhibitors, or their pharmaceutically acceptable salts,and one or more alpha agonists or antagonists, or their pharmaceuticallyacceptable salts. The invention further provides for a method forameliorating or reducing presbyopia of a patient having an eye,comprising administering to the eye a therapeutically effective amountof an ophthalmic preparation comprising one or more parasympathomimeticdrugs or one or more cholinesterase inhibitors, or theirpharmaceutically acceptable salts, and one or more alpha agonists orantagonists, or their pharmaceutically acceptable salts. The inventionalso provides for a method of producing ocular miosis in a subject whichcomprises administering to the subject an amount of a preparationcomprising one or more parasympathomimetic drugs or one or morecholinesterase inhibitors, or their pharmaceutically acceptable salts,and one or more alpha agonists or antagonists, or their pharmaceuticallyacceptable salts, effective to produce ocular miosis.

In some embodiments, the one or more parasympathomimetic drugs ispilocarpine, or carbachol, or their pharmaceutically acceptable salts.In a further embodiment, the one or more alpha agonists is brimonidine,or a pharmaceutically acceptable salt thereof.

In some embodiments, the one or more cholinesterase inhibitor is anorganophosphate such as metrifonate, a carbamate such as physostigmine(also known as eserine), neostigmine (also known as prostigmine),pyridostigmine, ambenonium, demarcarium, or rivastigmine; a phenanthrenederivative such as galantamine; a piperidine compound such as donepezil,tacrine (also known as tetrahydroaminoacridine (THA′)), edrophonium,huperzine A, or ladostigil. In another embodiment, the cholinesteraseinhibitor may be diisopropyl fluorophosphate or DFP (Floropryl). Inother embodiments, the one or more cholinesterase inhibitors isphospholine iodide (also known as echothiophate) or physostigmine, orits pharmaceutically acceptable salt. In certain embodiments, the one ormore alpha antagonists is doxazosin, silodosin, prazosin, tamsulosin,alfuzosin, terazosin, trimazosin, phenoxybenzamine, or phentolamine, ora pharmaceutically acceptable salt thereof.

In some embodiments, brimonidine, or a pharmaceutically acceptable saltthereof, is present in an amount less than about 0.2%. In otherexemplary embodiments, the one or more parasympathomimetic drugs ispilocarpine, or its pharmaceutically acceptable salt, which is presentin the preparation in an amount less than about 0.5%. In furtherexemplary embodiments, the one or more parasympathomimetic drugs ispilocarpine, or its pharmaceutically acceptable salt, which is presentin the preparation in an amount of less than about 0.1%.

In some further embodiments, the one or more parasympathomimetic drugsis carbachol, or its pharmaceutically acceptable salt, which is presentin the preparation in an amount of about 5%. In certain embodiments, theone or more parasympathomimetic drugs is carbachol, or itspharmaceutically acceptable salt, which is present in the preparation inan amount of no more than 0.001%.

In some further embodiments, the one or more alpha antagonist isphentolamine, or its pharmaceutically acceptable salt, which is presentin the preparation in an amount of no more than 2%. In certainembodiments, the one or more alpha antagonist is phentolamine, or itspharmaceutically acceptable salt, which is present in the preparation inan amount of no more than 0.005%.

DETAILED DESCRIPTION OF THE EMBODIMENTS

This application relates to a pharmaceutical preparation comprising oneor more parasympathomimetic drugs and one or more alpha agonists. In oneembodiment, the one or more parasympathomimetic drug is pilocarpine. Inanother embodiment, one or more parasympathomimetic drug is carbachol.In further embodiments, the one or more parasympathomimetic drugs arepilocarpine and carbachol. In certain embodiments, the one or more alphaagonists is brimonidine, or a pharmaceutically acceptable salt thereof.The ophthalmic preparation may be administered to a subject sufferingfrom presbyopia as often as needed to cause miosis sufficient totemporarily treat, ameliorate, or reduce presbyopia. Thus, the inventionfurther provides a method for temporarily treating, ameliorating, orreducing presbyopia by inducing miosis.

The invention also relates to a method for ameliorating or reducingpresbyopia of a patient having an eye, comprising administering to saideye a therapeutically effective amount of an ophthalmic preparationcomprising one or more parasympathomimetic drugs or cholinesteraseinhibitors, or pharmaceutically acceptable salts thereof, and one ormore alpha agonists or antagonists, or pharmaceutically acceptable saltsthereof.

In one embodiment, the invention is directed to a method of reducing oreliminating dimness of vision of a patient having an eye comprisingadministering to said eye a therapeutically effective amount of anophthalmic preparation comprising one or more parasympathomimetic drugsor cholinesterase inhibitors, or pharmaceutically acceptable saltsthereof, and one or more alpha agonists or antagonists, orpharmaceutically acceptable salts thereof.

In some embodiments, the invention is directed to a method of improvingfocus and/or correcting refractive errors of a patient having an eyecomprising administering to said eye a therapeutically effective amountof an ophthalmic preparation comprising one or more parasympathomimeticdrugs or cholinesterase inhibitors, or pharmaceutically acceptable saltsthereof, and one or more alpha agonists or antagonists, orpharmaceutically acceptable salts thereof. Although brimonidine is notordinarily used to constrict the pupil, and thus enhance visual acuity,applicants discovered that it potentiates the effect of pilocarpine onthe pupil. Thus, an embodiment of the present application is a methodfor ameliorating or reducing presbyopia of a patient by applying to theone or both eyes of the patient a therapeutically effective amount ofpilocarpine, or pharmaceutically acceptable salts thereof, and aneffective amount of brimonidine, or pharmaceutically acceptable saltsthereof. Another embodiment of the present application is a method forameliorating or reducing presbyopia of a patient by applying to the oneor both eyes of the patient a therapeutically effective amount ofcarbachol, or pharmaceutically acceptable salts thereof, and aneffective amount of brimonidine, or pharmaceutically acceptable saltsthereof. In some embodiments, the two drugs are administered as a singlecombined ophthalmic preparation. In another embodiment, the two drugsare formulated or as two separate ophthalmic preparations and applied tothe eye successively or simultaneously.

Brimonidine should also potentiate the effect on the pupil of otherparasympathomimetic drugs such as acetylcholine, muscarine, nicotine,suxamethonium, bethanechol, carbachol, methacholine,phenylpropanolamine, amphetamine, ephedrine, phentolamine, andfenfluramine) as well as cholinesterase inhibitors such as metrifonate,neostigmine (prostigmine), pyridostigmine, ambenonium, demarcarium,rivastigmine, galantamine, donepezil, tacrine (tetrahydroaminoacridine),edrophonium, huperzine A, ladostigil, diisopropyl fluorophosphate(Floropryl), phospholine iodide (echothiophate) or physostigimine(eserine).

It may also be beneficial to administer the pharmaceutical preparationsdescribed herein to only a single eye of a patient. In some instances,blurring of distance vision (a result of accommodative focus) anddimness of vision (a result of pupil constriction) may occur when thecompositions are administered to both eyes of a patient. When applied toonly a single eye, the benefits of improvement in presbyopia areobtained with diminished or complete relief of blurring and dimness.Without being bound to any particular theory, it is believed that apatient's brain compensates between the treated and untreated eyesthereby reducing the undesired effects. The combination of a constrictedpupil with its increased depth of field in the treated eye and normaldistance vision and brightness in the untreated eye will cause the brainto ignore any monocular blur at distance or near vision.

As used herein, the term “parasympathomimetic agent or drug” is intendedto include to any cholinergic drug that enhances the effects mediated byacetylcholine in the central nervous system, the peripheral nervoussystem, or both. Examples of these so-called acetylcholine receptoragonists suitable for the preparations and methods of the presentinvention include acetylcholine, muscarine, pilocarpine, nicotine,suxamethonium, bethanechol, carbachol, methacholine,phenylpropanolamine, amphetamine, ephedrine, phentolamine, andfenfluramine

As used herein, the term “alpha agonist” refers to compounds thatpreferentially stimulate alpha (both alpha1 and alpha2) adrenoceptors.Examples of alpha androgenic agonist suitable for the preparations andmethods of the present invention include amiloride, apraclonidine,brimonidine, clonidine (and its derivatives such as p-chloro and aminoderivatives), detomidine, dexmedetomidine, dipivalylepinephrine,epinephrine, guanabenz, guanfacine, isoproterenol, medetomidine,metaproterenol, mephentermine, methoxamine, methyldopa, naphazoline,norepinephrine, phenylephrine, rilmenidine, salbutamol, terbutaline,tetrahydrozoline, and xylazine and their pharmaceutically acceptablesalts and prodrugs.

In the subject invention a “therapeutically effective amount” is anyamount of the two or more active ingredients present in the preparationof the present invention which, when administered to a subject sufferingfrom presbyopia are effective to cause miosis sufficient to temporarilyreduce, ameliorate, or treat presbyopia such that the near vision of thetreated eye is temporarily restored partially or completely. A completerestoration of the near vision should be sufficient to allow the personto read a Times New Roman font of size 12 without any other aid. Apartial restoration of near vision will allow the treated eye to seewith decreased blurriness. Thus, a therapeutically effective amountrefers to the amount of a therapeutic preparation that reduces theextent of presbyopia by at least 10%, at least 20%, at least 30%, atleast 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100%. For certain embodiments, the amount of theophthalmic preparation comprising the one or more parasympathomimeticdrugs and the one or more alpha agonists is effective to ameliorate orreduce presbyopia for about 12 hours, 11 hours, 10 hours, 9 hours, 8hours, 7 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours or 1 hour.The extent of presbyopia can be determined by any method known in theart for ophthalmic examination.

The terms “ameliorate, ameliorating, and amelioration,” as used herein,are intended to refer to a decrease in the severity of presbyopia. Theamelioration may be complete, e.g., the total absence of presbyopia. Theamelioration may also be partial, such that the amount of presbyopia isless than that which would have been present without the presentinvention. For example, the extent of presbyopia-using the methods ofthe present invention may be at least 10%, at least 20%, at least 30%,at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, atleast 90%, or at least 100% less than the amount of presbyopia thatwould have been present without the present invention.

The pharmaceutical preparations of the present invention are adapted fortopical administration to the eye in the form of solutions, suspensions,ointments, or creams. The ophthalmic pharmaceutical preparation of thepresent invention may be used in the form of an eyewash, ophthalmicsolution (e.g., eye drop), or ophthalmic ointment.

The ophthalmic pharmaceutical preparation of the present invention maybe prepared using commonly used pharmaceutically-acceptable carriers insuch a manner of mixing them with an effective amount of the one or moreparasympathomimetic drugs and one or more alpha agonists to suit thedesired formulation. The carriers used for ophthalmic solutions andeyewashes include any one of those which are commonly used therefor,usually, purified water. The ophthalmic pharmaceutical preparation ofthe present invention can be previously prepared into a solution form orprocessed into a solid preparation using lyophilization method, etc., tobe used in the desired preparation, for example, dissolving the solidpreparation in the desired liquid carrier. Examples of such a solidpreparation include tablets, granules, and powders. These ophthalmicpharmaceutical preparations can be prepared in accordance withconventional methods and should preferably be sterilized before use byconventional methods using membrane filters, autoclaves, etc. Theophthalmic preparations may comprise saccharides such as glucose andmaltose; sugar alcohols such as mannitol and sorbitol; electrolytes suchas sodium chloride, sodium hydrogenphosphate, potassium chloride,magnesium sulfate, and calcium chloride; amino acids such as glycine andalanine; vitamins and derivatives thereof such as thiaminehydrochloride, sodium riboflavin phosphate, pyridoxine hydrochloride,nicotinamide, folic acid, biotin, vitamin A, L-ascorbic acid, andα-glycosyl-L-ascorbic acid, which all can be used in an appropriatecombination. Particularly, in the case of the ophthalmic pharmaceuticalpreparation of the present invention is in the form of an ophthalmicsolution, the combination use of the one or more parasympathomimeticdrugs and one or more alpha agonists as an effective ingredient and oneor more other saccharides selected from monosaccharides such as glucoseand fructose, disaccharides such as maltose, and oligosaccharides higherthan maltotriose may stably exert a satisfactory therapeutic effect. Inaddition, viscosity-imparting agents such as methyl cellulose, carboxymethyl cellulose, chondroitin sulfate, polyvinyl alcohol, and pullulan;solubilizers such as polysorbate 80 may be used in the preparations.

In some embodiments, the composition of the present invention may beformulated as a powder substantially free of water wherein thecomposition is reconstituted to a solution, a suspension, an ointment,or a cream just prior to use by the patient or a treating physician.Some embodiments may contain the active ingredients and other excipientsbut are free of water. Of course, the active ingredient and/or one ormore excipient may be hygroscopic and as such may contain small amountof water. Some embodiments contain no more than 0.1%, 0.5%, 1%, 2%, 3%,4%, 5%, 6%, 7%, 8%, 9%, or 10% by weight of water in the composition.

The preparations may contain from about 0.0001% to about 5% for each ofthe one or more parasympathomimetic drugs and the one or more alphaagonists.

In one embodiment, the preparation comprises brimonidine and aparasympathomimetic drug. In another embodiment, the parasympathomimeticdrug is pilocarpine. In a further embodiment, the parasympathomimeticdrug is carbachol. In another embodiment, the parasympathomimetic agentis phentermine.

The one or more parasympathomimetic drugs and the one or more alphaagonists may be present in the pharmaceutical preparation as apharmaceutically acceptable addition salt. Pharmaceutically acceptablesalts are well known in the art and refer to the relatively non-toxic,inorganic and organic acid addition salts of the compound of the presentinvention. The salts can be prepared in situ during the final isolationand purification of the compounds of the invention, or separately byreacting the free base function with a suitable organic acid. Examplesof pharmaceutically acceptable, nontoxic acid addition salts are saltsof an amino group formed with inorganic acids such as hydrochloric acid,hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid orwith organic acids such as acetic acid, oxalic acid, maleic acid,tartaric acid, citric acid, succinic acid or malonic acid or by usingother methods used in the art such as ion exchange. Otherpharmaceutically acceptable salts include adipate, alginate, ascorbate,aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate,camphorate, camphorsulfonate, citrate, cyclopentanepropionate,digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate,glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate,hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate,laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Representative alkali or alkaline earth metal salts includesodium, lithium, potassium, calcium, magnesium, and the like. Furtherpharmaceutically acceptable salts include, when appropriate, nontoxicammonium, quaternary ammonium, and amine cations formed usingcounterions such as halide, hydroxide, carboxylate, sulfate, phosphate,nitrate, loweralkyl sulfonate and aryl sulfonate.

In certain embodiments, at least one of the drugs is present in anamount lower than 75% of its effective dose for the purpose for which itis used when administered alone. For example, when pilocarpine is thedrug which may be present in an amount lower than 75% of its dosage whenused alone, then pilocarpine may be present in the preparation at morethan about 3%.

When the alpha2 agonist present in the preparation is brimonidine, someembodiments may include about 0.3% or less, no more than 0.25%, no morethan 0.2%, no more than 0.19%, no more than 0.18%, no more than 0.17%,no more than 0.16%, no more than 0.15%, no more than 0.14%, no more than0.13%, no more than 0.12%, no more than 0.11%, or no more than 0.1%brimonidine or its pharmaceutically acceptable salt.

When the alpha2 agonist present in the preparation is naphazoline, someembodiments may include about 0.2% or less, no more than 0.15%, no morethan 0.125%, no more than 0.12%, no more than 0.11%, no more than 0.10%,no more than 0.09%, no more than 0.08%, no more than 0.07%, no more than0.06%, no more than 0.05% naphazoline or its pharmaceutically acceptablesalt. In some embodiments containing pilocarpine, or a pharmaceuticallyacceptable salt thereof, as the parasympathomimetic drug, theformulations may contain about 3% or less, no more than 2.8%, no morethan 2.6%, no more than 2.5%, no more than 2.3%, no more than 2.0%, nomore than 1.8%, no more than 1.6%, no more than 1.5%, no more than 1.2%,no more than 1%, no more than 0.9%, no more than 0.8%, no more than0.7%, no more than 0.6%, no more than 0.5%, no more than 0.4%, no morethan 0.3%, no more than 0.275%, no more than 0.25%, no more than 0.225%,no more than 0.2%, no more than 0.175%, no more than 0.15%, no more than0.125%, no more than 0.1%, no more than 0.09%, no more than 0.08%, nomore than 0.07%, no more than 0.06%, no more than 0.05%, no more than0.04%, no more than 0.03%, no more than 0.02%, no more than 0.01%, nomore than 0.005%, no more than 0.0025%, no more than 0.00125%, or nomore than 0.001% of pilocarpine or its pharmaceutically acceptable salt.

When the parasympathomimetic drug present in the formulation iscarbachol, or its pharmaceutically acceptable salt, some embodiments maycontain about 5% or less, no more than 4.5%, no more than 4%, no morethan 3.5%, no more than 3%, no more than 2.75%, no more than 2.5%, nomore than 2.25%, no more than 2%, no more than 1.75%, no more than 1.5%,no more than 1.25%, no more than 1%, no more than 0.75%, no more than0.5%, no more than 0.4%, no more than 0.3%, no more than 0.2%, or nomore than 0.1% carbachol or its pharmaceutically acceptable salt.

Certain embodiments may contain phentolamine, or a pharmaceuticallyacceptable salt thereof, as the alpha antagonist. In those embodiments,the preparation may contain about 5% or less, no more than 4%, no morethan 3.5%, no more than 3%, no more than 2.5%, no more than 2%, no morethan 1.8%, no more than 1.6%, no more than 1.4%, no more than 1.2%, nomore than 1%, no more than 0.9%, no more than 0.8%, no more than 0.7%,no more than 0.6%, no more than 0.5%, no more than 0.4%, no more than0.3%, no more than 0.275%, no more than 0.25%, no more than 0.225%, nomore than 0.2%, no more than 0.175%, no more than 0.15%, no more than0.125%, no more than 0.1%, no more than 0.09%, no more than 0.08%, nomore than 0.07%, no more than 0.06%, no more than 0.05%, no more than0.04%, no more than 0.03%, no more than 0.02%, no more than 0.01%, nomore than 0.005%, no more than 0.0025%, no more than 0.00125%, or nomore than 0.001% of phentolamine or its pharmaceutically acceptablesalt.

In some embodiments, the one or more cholinesterase inhibitors isphospholine iodide (echothiophate) or its pharmaceutically acceptablesalt, for example iodide salt. In some embodiments, the phospholineiodide is present in the preparation in an amount of about 0.001% toabout 1%. Certain embodiments containing phospholine iodide contain nomore than about 0.03%, no more than about 0.06%, no more than about0.125%, or no more than about 0.25% of the cholinesterase inhibitor. Inother embodiments, phospholine iodide is present in the preparation inan amount of about 0.001% to about 0.1%. In further embodiments,phospholine iodide is present in the preparation in no more than 0.01,0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, or0.5%. In one embodiment, the echothiophate salt is an iodide saltpresent in the preparation in no more than 2, 1.9, 1.8, 1.7, 1.6, 1.5,1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1,0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, or 0.005%.

In one embodiment, the one or more cholinesterase inhibitors is aphysostigmine salt (eserine), for example a salicylate salt, which ispresent in the preparation in an amount ranging from about 0.01% toabout 2%. In further embodiments, physostigmine salicylate is present inthe preparation in no more than 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3,1.2, 1.1, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08,0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, or 0.005%.

In another embodiment, the one or more cholinesterase inhibitors isrivastigmine salt, for example tartarate salt, which is present in thepreparation in an amount ranging from about 0.01% to about 2%. Infurther embodiments, rivastigmine salt is present in the preparation inno more than 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9,0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05,0.04, 0.03, 0.02, 0.01, or 0.005%.

In a certain embodiment, the one or more cholinesterase inhibitors isdonepezil, for example hydrochloride salt, which is present in thepreparation in an amount ranging from about 0.01% to about 2%. Infurther embodiments, donepezil is present in the preparation in no morethan 2, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1.0, 0.9, 0.8, 0.7,0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03,0.02, 0.01, or 0.005%. In a further embodiment, the one or morecholinesterase inhibitors, such as donepezil hydrochloride andrivastigmine tartarate, may be present in the preparation in an amountof about 0.001% to about 0.1%. In some embodiments, donepezilhydrochloride or rivastigmine tartarate is present in the preparation inno more than 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1,0.2, 0.3, 0.4, or 0.5%.

Unless otherwise specified elsewhere, the “%” in dosages in thepreparations are intended to signify weight percentages.

When the “%” of a monomer in a co-polymer is specified, then thatpercentage is intended to mean mole (or repeat unit) percent. Thus, incopolymers, repeat units of each monomer are counted to calculate thetotal number of units of each monomer present in the co-polymer. Forexample, a co-polymer of two monomers containing on average (numberaverage) three units of one monomer (say monomer A) for every sevenunits of another monomer (say monomer B) is said to contain 30% monomerA and 70% monomer B.

The pharmaceutical preparation which contains the one or moreparasympathomimetic drugs and the one or more alpha agonists may beconveniently admixed with a non-toxic pharmaceutical organic carrier, orwith a non-toxic pharmaceutical inorganic carrier. Typical ofpharmaceutically acceptable carriers are, for example, water, mixturesof water and water-miscible solvents such as lower alkanols oraralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly,ethyl cellulose, ethyl oleate, carboxymethyl-cellulose,polyvinylpyrrolidone, isopropyl myristate and other conventionallyemployed acceptable carriers. The pharmaceutical preparation may alsocontain non-toxic auxiliary substances such as emulsifying, preserving,wetting agents, bodying agents and the like, as for example,polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500,4,000, 6,000 and 10,000, antibacterial components such as quaternaryammonium compounds, phenylmercuric salts known to have cold sterilizingproperties and which are non-injurious in use, thimerosal, methyl andpropyl paraben, benzyl alcohol, phenyl ethanol, buffering ingredientssuch as sodium borate, sodium acetates, gluconate buffers, and otherconventional ingredients such as sorbitan monolaurate, triethanolamine,oleate, polyoxyethylene sorbitan monopalmitylate, dioctyl sodiumsulfosuccinate, monothioglycerol, thiosorbitol, ethylenediaminetetracetic acid, and the like. Additionally, suitable ophthalmicvehicles can be used as carrier media for the present purpose includingconventional phosphate buffer vehicle systems, isotonic boric acidvehicles, isotonic sodium chloride vehicles, isotonic sodium boratevehicles and the like.

The pharmaceutical preparation may contain non-toxic auxiliarysubstances such as antibacterial components which are non-injurious inuse, for example, thimerosal, benzalkonium chloride, methyl and propylparaben, benzyldodecinium bromide, benzyl alcohol, or phenylethanol;buffering ingredients such as sodium chloride, sodium borate, sodiumacetate, sodium citrate, or gluconate buffers; and other conventionalingredients such as sorbitan monolaurate, triethanolamine,polyoxyethylene sorbitan monopalmitylate, ethylenediamine tetraaceticacid, and the like.

The pharmaceutical preparation may contain a buffering agent to maintainthe pH in the therapeutically useful range of about 4.5 to 8.5. Incertain embodiments, the pH is adjusted to about 5-8. In otherembodiments, the pH is adjusted to about 6-7.5. In other embodiments,the pH is adjusted to about 7.3. Buffering agents used are those knownto those skilled in the art, and, while not intending to be limiting,some examples are acetate, borate, carbonate, citrate, and phosphatebuffers. In one embodiment of this invention, boric acid is thebuffering agent.

The pharmaceutical preparations may contain one or more emulsifiers. Asused herein, an “emulsifier” promotes the formation and/or stabilizationof an emulsion. Suitable emulsifiers may be natural materials, finelydivided solids, or synthetic materials. Natural emulsifying agents maybe derived from either animal or vegetable sources. Those from animalsources include gelatin, egg yolk, casein, wool fat, or cholesterol.Those from vegetable sources include acacia, tragacanth, chondrus, orpectin. Vegetable sources specifically from cellulose derivativesinclude methyl cellulose and carboxymethyl cellulose to increase theviscosity. Finely divided emulsifiers include bentonite, magnesiumhydroxide, aluminum hydroxide, or magnesium trisylicate. Syntheticagents include anionic, cationic or nonionic agents. Particularly usefulare sodium lauryl sulfate, benzalkonium chloride or polyethylene glycol400 monostearate, or any combinations thereof.

The pharmaceutical preparations may contain one or more thickeners. Asused herein, a “thickener” refers to an agent that makes the preparationof the present invention dense or viscous in consistency. Suitablethickeners that can be used in the context of the present inventioninclude, for example, non-ionic water-soluble polymers such ashydroxyethylcellulose (commercially available under the TrademarkNatrosol® 250 or 350), cationic water-soluble polymers such as Polyquat37 (commercially available under the Trademark Synthalen® CN), fattyalcohols, fatty acids, anionic polymers, and their alkali salts andmixtures thereof.

The pharmaceutical preparations may contain one or more solubilizingagents. As used herein, the term “solubilizing agents” refers to thosesubstances that enable solutes to dissolve. Representative examples ofsolubilizing agents that are usable in the context of the presentinvention include, without limitation, complex-forming solubilizers suchas citric acid, ethylenediamine-tetraacetate, sodium meta-phosphate,succinic acid, urea, cyclodextrin, polyvinylpyrrolidone,diethylammonium-ortho-benzoate, and micelle-forming solubilizers such asTWEEN® and spans, e.g., TWEEN 80®. Other solubilizers that are usablefor the preparations of the present invention are, for example,polyoxyethylene sorbitan fatty acid ester, polyoxyethylene n-alkylethers, n-alkyl amine n-oxides, polyoxamers, organic solvents, such asacetone, phospholipids and cyclodextrins.

The pharmaceutical preparation may contain a mucoadhesive. As usedherein, the term “mucoadhesive” means a natural or synthetic component,including macromolecules, polymers, and oligomers, or mixtures thereof,that can adhere to a subject's mucous membrane. Adhesion ofmucoadhesives to the mucous membrane occurs primarily throughnoncovalent interactions, such as hydrogen bonding and Van der Waalforces. Examples of mucoadhesives for use in the embodiments disclosedherein include, but are not limited to, Carbopol®, pectin, alginic acid,alginate, chitosan, hyaluronic acid, polysorbates, such aspolysorbate-20, -21, -40, -60, -61, -65, -80, -81, -85;poly(ethyleneglycol), such as PEG-7, -14, -16, -18, -55, -90, -100,-135, -180, -4, -240, -6, -8, -9, -10, -12, -20, or -32;oligosaccharides and polysaccharides, such as Tamarind seedpolysaccharide, gellan, carrageenan, xanthan gum, gum Arabic, anddextran; cellulose esters and cellulose ethers; modified cellulosepolymers, such as carboxymethylcellulose, hydroxyethylcellulose,hydroxypropyl methylcellulose, hydroxyethyl ethylcellulose; polyetherpolymers and oligomers, such as polyoxyethylene; condensation productsof poly(ethyleneoxide) with various reactive hydrogen containingcompounds having long hydrophobic chains (e.g. aliphatic chains of about12 to 20 carbon atoms), for example, condensation products ofpoly(ethylene oxide) with fatty acids, fatty alcohols, fatty amides,polyhydric alcohols; polyether compounds, such as poly(methyl vinylether), polyoxypropylene of less than 10 repeating units; polyethercompounds, such as block copolymers of ethylene oxide and propyleneoxide; mixtures of block copolymers of ethylene oxide and propyleneoxide with other excipients, for example poly(vinyl alcohol);polyacrylamide; hydrolyzed polyacrylamide; poly(vinyl pyrrolidone);poly(methacrylic acid); poly(acrylic acid) or crosslinked polyacrylicacid, such as Carbomer®, i.e., a homopolymer of acrylic acid crosslinkedwith either an allyl ether of pentaerythritol, an allyl ether ofsucrose, or an allyl ether of propylene. In certain embodiments themucoadhesive is a polysaccharide. One polysaccharide which isparticularly useful as a mucoadhesive in the embodiments disclosedherein is Tamarind seed polysaccharide, which is a galactoxyloglucanthat is extracted from the seed kernel of Tamarindus Indica, and can bepurchased from TCI America of Portland, Oreg.

The pharmaceutical preparations may contain a tonicity agent to adjustthe preparation to the desired isotonic range. Tonicity agents are knownto those skilled in the ophthalmic art, and, while not intending to belimiting, some examples include glycerin, mannitol, sorbitol, sodiumchloride, and other electrolytes. In one embodiment, the tonicity agentis glycerin. In another embodiment, the tonicity agent is a chloridesalt. In some embodiments, the ionic content adjusted to about 0.5% toabout 1.8%, expressed as sodium chloride equivalents. In theseembodiments, the preparation may, in addition to tonicity adjustingingredients, comprise an ophthalmically acceptable, water-soluble,non-ionic synthetic polymer having a molecular weight within the rangeof 300 to 250,000, and a non-charged, non-ionic tonicity adjustingagent.

The exact percentage of the non-ionic synthetic polymer used in thesolution will depend on the molecular weight of the selected polymer.However, it is intended that, absent the presence of additionalviscosity building agents, the ophthalmic solution will generally have aviscosity between about 1 to about 10 cps. In certain embodiments, theophthalmic solution has a viscosity of about 2 cps to about 8 cps at 23°C. For example, polyvinyl alcohol and polyethylene glycol are amongthose non-ionic polymeric substances that may be incorporated into thepreparations of the present invention. When polyvinyl alcohol is addedto the solution, it will be present in a concentration of from about0.1% to about 5%, or even from about 0.25% to about 2%, whereas whenpolyethylene glycol is used it will comprise from about 0.25% to about3% of the solution. Such polymers are commercially available and theircomposition well known to those skilled in the art.

The pharmaceutical preparation may contain a preservative. Preservativesare used to prevent bacterial contamination in multiple-use ophthalmicpreparations, and, while not intending to be limiting, examples includebenzalkonium chloride, stabilized oxychloro complexes (otherwise knownas Purite®), phenylmercuric acetate, chlorobutanol, benzyl alcohol,parabens, and thimerosal. In some embodiments, the preservative isPurite®.

The pharmaceutical preparation may contain a chelating agent to enhancepreservative effectiveness. Suitable chelating agents are those known inthe art, and, while not intending to be limiting, edetate salts likeedetate disodium, edetate calcium disodium, edetate sodium, edetatetrisodium, and edetate dipotassium are examples of useful preservatives.

The pharmaceutical preparations of the present invention may beformulated as sustained release formulation wherein the activeingredients are released over several hours. For example, a stable fluidpreparation for the sustained release preparation may comprise asynthetic polymer comprising both hydrophilic and hydrophobic componentssuch that the active ingredients become encapsulated or dispersed inmicellar droplets.

The polymer may be a homopolymer of a monomer containing a pendenthydrophilic group such as an acid group, or it may be a copolymer ofdifferent monomers, some or all of which contain pendent hydrophilicgroups such as an acid group. The monomers may be vinyl monomers. Theco-polymer may contain about 10% or more of the monomer containing thehydrophilic pendent group. In one embodiment, more than 25% by weight ofthe monomers contain a hydrophilic pendent group. In another embodiment,more than 40% by weight of the monomers contain a hydrophilic pendentgroup. In certain embodiments, 10-100% by weight of the monomers containa hydrophilic pendent group and 0-90% of monomers are hydrophobicmonomers. In other embodiments, 25-100% by weight of the monomerscontain a hydrophilic pendent group and 0-75% of monomers arehydrophobic monomers. In further embodiments, 40-100% by weight of themonomers contain a hydrophilic pendent group, and 0-60% of monomers arehydrophobic monomers.

The particular choice of monomers will be made having regard to thedesired solubility or dispersability of the polymer, the desired releasepattern and other properties required of the particular formulation.Although the polymers used in the present preparations are generallyfree of cross-linking agent and comprise both hydrophilic monomers andhydrophobic monomers, cross-linking may be used as additional control ofthe properties of the polymer. For instance, by including a small amountof a trifunctional cross-linkable monomer may be added to the monomermixture from which the polymer is made. The amount of cross-linkablemonomer is generally small, for instance 1-15% by weight, or 1-10% byweight. In certain embodiments, the polymers may comprise from 10 to 75%hydrophilic monomers and from 20 to 80% hydrophobic monomers. In otherembodiments, the polymers may comprise from 10 to 55% hydrophilicmonomers and from 30 to 60% hydrophobic monomers.

Suitable hydrophilic monomers include monomeric acids, such as acrylic,methacrylic, itaconic, crotonic, vinyl sulfonic, maleic, angelic, oleic,or .alpha.-chloro-acrylic acid or sulfoethyl-methacrylate and vinylpyrrolidone. Naturally dicarboxylic acids such as maleic acid may beintroduced in the form of the anhydride.

Suitable hydrophobic monomers include alkyl acrylates, alkylmethacrylates, vinyl ethers, acrylonitrile, hydroxymethacrylate, styreneand vinyl acetate. The alkyl groups in alkylacrylates andalkylmethacrylates usually contain 1 to 4 carbon atoms, e.g. ethyl,methyl or butyl, but longer chain groups containing up to, say, 18carbon atoms, e.g., lauryl, can be used. In particular when hydrophobicmonomer is present, at least part of it can be a plasticizing monomer ina proportion of 5% to 20% by weight. In certain embodiments, theplasticizing monomer makes about 10% of the polymer. Suitableplasticizing monomers are long chain esters of acrylic or methacrylicacid, e.g. ethyl hexyl acrylate.

In certain embodiments, the polymer is a copolymer of hydrophilicmonomers selected from acrylic acid, vinyl pyrrolidone, methacrylic acidand maleic anhydride and hydrophobic monomers selected from methylmethacrylate, butyl methacrylate, lauryl methacrylate, methylacrylate,2-ethyl-hexylacrylate and styrene. In another embodiment, the polymermay include acrylic acid with or without vinyl pyrrolidone. In certainembodiments, the polymer may contain from 20 to 55% acrylic acid.

EXAMPLE 1 Ophthalmic Solution in 100 ml

Ingredient Amount Brimonidine or its pharmaceutically acceptable 0.1,0.15, 0.2, or 0.25 g salt carbachol or its pharmaceutically acceptable5, 4.5, 4, 3.5, 3, 2.75, salt 2.5, 2.25, 2, 1.75, 1.5, 1.25, 1, 0.75, or0.5 g Sodium chloride 0.4 g D-Glucose 0.04 g Sterilized refined waterBalance Total 100 ml

The above ingredients are prepared in a usual manner into a sterilizedpreparation as an ophthalmic solution, adjusting, if necessary, the pHto about 7.3. This example provides for sixty different ophthalmicpreparations.

EXAMPLE 2 Ophthalmic Solution in 100 ml

Ingredient Amount Brimonidine or its pharmaceutically 0.1, 0.15, 0.2, or0.25 g acceptable salt pilocarpine or its pharmaceutically 3, 2.8, 2.6,2.5, 2.3, 2.0, 1.8, acceptable salt 1.6, 1.5, 1.2, 1, 0.9, 0.8, 0.7,0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 g Sodium chloride 0.4 g D-Glucose 0.04 gSterilized refined water Balance Total 100 ml

The above ingredients are prepared in a usual manner into a sterilizedpreparation as an ophthalmic solution, adjusting, if necessary, the pHto 7.3 using a buffer solution. This example provides for eightydifferent ophthalmic preparations.

EXAMPLE 3 Ophthalmic Solution in 100 ml

Ingredient Amount Brimonidine or its pharmaceutically acceptable 0.1,0.15, 0.2, or 0.25 g salt phentolamine or its pharmaceutically 0.1, 0.2,or 0.4 g acceptable salt Sodium chloride 0.4 g D-Glucose 0.04 gSterilized refined water Balance Total 100 ml

The above ingredients are prepared in a usual manner into a sterilizedpreparation as an ophthalmic solution, adjusting, if necessary, the pHto 7.3 using a buffer solution. This example provides for twelvedifferent ophthalmic preparations.

EXAMPLE 4

The effect of pilocarpine alone or in combination with brimonidine onnear visual acuity (VA) for patients suffering from presbyopia wasevaluated. Initially, 10 patients were selected for preliminaryevaluation. Each patient was administered with one drop of a formulationcontaining 0.25%, 0.5%, or 1.0% pilocarpine with or without one drop ofa formulation containing 0.2% brimonidine. Thus, the following sixdosages were initially tested:

1. 0.25% pilocarpine,

2. 0.5% pilocarpine,

3. 1.0% pilocarpine,

4. 0.25% pilocarpine and 0.2% brimonidine,

5. 0.5% pilocarpine and 0.2% brimonidine, and

6. 1.0% pilocarpine and 0.2% brimonidine.

FIG. 1 shows change in visual acuity at 1 hr, 2 hrs, and 4 hrs afteradministration of one of the six dosages described above. Table 1 showsthe effect of the six formulations on pupil diameter and visual acuityof the six formulations. Although some patients displayed burningsymptoms on their eyes, it should be noted that the formulations werenot optimized for patient comfort. All six dosages provided some(varying) initial improvement in visual acuity. However, the effect offormulations containing pilocarpine alone appears to wear out fairlyquickly whereas it takes longer time for effects of formulationscontaining both drugs to wear out.

To further understand the effectiveness of the formulation containing0.5% pilocarpine and 0.2% brimonidine, applicant conducted adouble-blind, randomized clinical trial. Forty patients suffering fromprsbyopia were recruited. The patients were randomly divided into twoarms: the active drug arm and the placebo arm. Prior to receiving thetreatment, the visual acuity of each patient was measured. On day 1 ofthe trial, patients enrolled in the active drug arm received one dropcontaining 0.5%, pilocarpine and one drop containing 0.2% brimonidine.The skilled artisan would recognize that the two drugs can be formulatedas a composition containing both drugs and applied the desired number ofdrops of the composition to the eye such that both drugs are deliveredto the eye simultaneously. Patients enrolled in placebo arm received twodrop of placebo. Patients' responses to the treatment were examined bymeasuring the visual acuity of each patient at 1, 2, 4, 8, and 10 hrsafter treatment. The treatment was repeated for seven days, each timeadministering the specified amount and examining patients' responses at1, 2, 4, 8, and 10 hrs after treatment by measuring their visual acuity.Table 2 lists patients' visual acuities, measured prior to the treatmentand at 1, 2, 4, 8, and 10 hrs after treatment for days 1 through 7.Although some patients displayed burning symptoms on their eyes, itshould be noted that the formulations were not optimized for patientcomfort.

FIG. 2 shows the average change in visual acuity at 1, 2, 4, 8, and 10hours after administration for the active drug and placebo arms. Thesolid squares represent the average change in visual acuity for theactive drug arm whereas the solid triangles represent the average changein visual acuity for the placebo arm. As can be seen from the data,there is a residual effect of the drug eight hours after administrationfor the active drug arm, allowing patients to read without correctivelenses for several hours.

Having now fully described the invention, it will be understood by thoseof ordinary skill in the art that the same can be performed within awide and equivalent range of conditions, formulations and otherparameters without affecting the scope of the invention or anyembodiment thereof.

TABLE 1 Pre-Treatment Pilo Alone Pupil 1 hr Right Eye Left Eye Diam NearVa Pilo nVA # Age Sex Sph Cyl Axis Sph Cyl Axis O.D. O.S. (j) [%] Pupil(J) 1 47 M 0 0 0 0 0 0 4.5 4.5 3 0.25 3.5 2 2 54 M 0 0 0 0 0 0 5.5 5.4 50.25 2.5 3 3 49 M 0 0 0 0 0 0 4 4 6 0.25 3.3 5 4 54 F 0 −0.5 20 0.5 −0.5160 3.5 3.5 8 0.25 3 6 5 53 F 0 0 0 0 0 0 4 4 6 0.5 2.5 3 6 47 F 0 0 0 00 0 4 4.3 5 0.5 3.8 3 7 53 F 0 0 0 0 −0.5 25 3.5 3.5 6 0.5 3 6 8 52 F 00 0 0 0 0 5 5 6 0.5 3 5 9 52 F 0 0 0 −0.5 −0.5 135 4.3 3.9 5 1 2.5 3 1053 F 0 0 0 0 0 0 3 3 8 1 1.5 3 11 53 F 0 0 0 −0.5 −0.25 175 4.5 4.5 5 12.5 2 12 52 F 0 0 0 0 0 0 4.5 4.5 10 1 3 8 Pilo Alone Pilo + Brimonidine2 hrs 4 hrs 1 hr 2 hrs 4 hrs nVA nVA Pilo nVA nVA nVA # Pupil (J) Pupil(J) [%] Pupil (J) Pupil (J) Pupil (J) 1 4 3 4 3 0.25 3 2 2.5 2 3.5 3 23.5 3 4 5 0.25 3.3 3 3.5 3 4 5 3 3 5 4 6 0.25 2.5 3 3 5 3.5 8 4 3.5 6 47 0.25 2 5 3 6 3.5 6 5 3 5 3.3 5 0.5 2 3 2.5 3 3.5 5 6 4 3 4 3 0.5 3 3 33 3.75 3 7 2.5 5 3 5 0.5 2.5 5 3 5 3 5 8 3.3 3 4.2 5 0.5 3 5 3 5 3 5 9 33 4 5 1 3 2 3 3 3.5 4 10 1.5 2 2.5 5 1 2 3 2 2 2.5 3 11 2.5 2 3 3 1 2 22 3 2.5 2 12 3 8 4 10 1 3 5 3 4 4 3

TABLE 2 PILOT STUDY - PILOCARPINE 0.5% PLUS BRIMONIDIE 0.2% EYE DROPSVS. PLACEBO TO REDUCE THE NEED FOR READING GLASSES (X 7 DAYS)Pre-treatment Day 1 Day 2 Near Near Near Near Near Near Near Near NearNear Near VA VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) VA(J) VA (J) Age Sex (j) 1 hr 2 hr 4 hr 8 hr 10 hr 1 hr 2 hr 4 hr 8 hr 10hr Pilocarpine 55 M 8 3 5 6 8 8 3 3 5 8 8 0.5% Plus 50 F 5 2 2 2 3 5 2 22 3 5 Brimonidine 55 F 8 5 5 6 7 8 4 5 5 6 8 0.2% Eye 48 F 8 3 2 5 8 8 33 5 8 8 Drops 49 F 6 3 5 5 5 6 4 5 5 5 6 48 M 3 1 1 1 2 3 1 1 1 1 2 52 M8 5 5 6 8 8 6 6 8 8 8 55 F 10 8 8 10 10 10 8 8 10 10 10 47 M 6 2 3 5 5 62 3 5 5 6 45 F 3 1 1 1 2 3 1 1 1 2 3 47 F 5 2 2 3 5 5 2 2 3 4 5 54 M 8 33 5 7 8 3 3 5 5 8 49 F 6 4 4 5 6 6 4 5 5 6 6 53 M 8 4 4 4 7 8 4 4 5 8 853 M 7 5 5 6 7 7 5 5 6 7 7 47 F 5 2 2 2 3 5 1 2 3 5 5 45 M 5 1 1 2 3 5 11 2 3 5 48 M 5 2 2 3 5 5 2 2 5 5 5 53 F 6 2 2 5 6 6 2 2 5 6 6 45 M 3 1 11 2 3 1 1 1 3 3 SUM 123 59 63 83 109 123 59 64 87 108 122 AVERAGE 6.152.95 3.15 4.15 5.45 6.15 2.95 3.2 4.35 5.4 6.1 Placebo 49 M 6 6 6 6 6 66 6 6 6 6 Eye 51 M 5 5 5 5 5 5 5 5 5 5 5 Drops 50 M 5 4 5 5 5 5 4 5 5 55 54 F 8 8 8 8 8 9 7 8 8 8 8 49 F 5 4 5 5 5 5 4 5 5 5 5 52 M 6 6 6 6 6 66 6 6 6 6 47 M 5 5 5 5 5 5 5 5 5 5 5 45 F 3 3 3 3 3 3 2 3 3 3 3 54 M 8 88 8 8 8 8 8 8 8 8 53 F 8 8 8 8 8 8 8 8 8 8 8 49 F 6 5 6 6 6 6 6 6 6 6 655 F 8 6 8 8 8 8 8 8 8 8 8 52 M 8 8 8 8 8 8 8 8 8 8 8 46 F 6 5 6 6 6 6 55 6 6 6 48 F 6 6 6 6 6 6 6 6 6 6 6 50 M 5 5 5 5 5 5 5 5 5 5 5 50 M 6 6 66 6 6 6 6 6 6 6 47 F 5 3 5 5 5 5 3 3 5 5 5 54 M 10 10 10 10 10 10 10 1010 10 10 45 F 3 2 3 3 3 3 2 3 3 3 3 SUM 122 113 122 122 122 123 114 119122 122 122 AVERAGE 6.1 5.65 6.1 6.1 6.1 6.15 5.7 5.95 6.1 6.1 6.1 Day 3Day 4 Near Near Near Near Near Near Near Near Near Near VA (J) VA (J) VA(J) VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) 1 hr 2 hr 4 hr 8 hr10 hr 1 hr 2 hr 4 hr 8 hr 10 hr Placebo 2 3 5 8 8 2 3 5 8 8 Eye 2 2 2 35 2 2 2 3 5 Drops 6 6 6 6 8 6 6 6 6 8 3 3 5 8 8 3 3 5 8 8 4 5 5 5 6 4 55 6 6 1 1 1 2 3 1 1 2 2 3 5 6 8 8 8 5 5 8 8 10 8 8 10 10 10 8 8 10 10 102 2 3 5 6 2 2 3 5 6 1 1 1 2 3 1 1 1 2 3 3 3 3 4 5 2 2 3 4 5 3 3 5 6 8 33 6 6 8 3 4 4 6 6 3 4 4 5 6 4 4 6 8 8 4 4 6 8 8 5 5 6 7 7 5 5 7 7 7 1 13 3 5 1 1 2 5 5 1 1 2 3 5 1 1 3 3 5 2 2 3 3 5 2 2 3 5 5 2 2 5 6 6 2 2 56 6 1 1 1 3 3 1 1 1 2 3 SUM 59 63 84 106 123 58 61 87 109 125 AVERAGE2.95 3.15 4.2 5.3 6.15 2.9 3.05 4.35 5.45 6.25 Placebo 6 6 6 6 6 6 6 6 66 Eye 5 5 5 5 5 5 5 5 5 5 Drops 4 5 5 5 5 4 5 5 5 5 8 8 8 8 8 8 8 8 8 84 5 5 5 5 4 5 5 5 5 6 6 6 6 6 6 6 6 6 6 5 5 5 5 5 5 5 5 5 5 2 3 3 3 3 23 3 3 3 8 8 8 8 8 8 8 8 8 8 7 8 8 8 8 7 8 8 8 8 6 6 6 6 6 6 6 6 6 6 8 88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 5 6 6 6 6 5 6 6 6 6 6 6 6 6 6 6 6 66 6 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 3 5 5 5 5 3 5 5 5 5 10 10 1010 10 10 10 10 10 10 2 3 3 3 3 2 3 3 3 3 SUM 114 122 122 122 122 114 122122 122 122 AVERAGE 5.7 6.1 6.1 6.1 6.1 5.7 6.1 6.1 6.1 6.1 Day 5 Day 6Near Near Near Near Near Near Near Near Near Near VA (J) VA (J) VA (J)VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) VA (J) 1 hr 2 hr 4 hr 8 hr 10hr 1 hr 2 hr 4 hr 8 hr 10 hr Placebo 3 3 5 8 8 3 3 5 8 8 Eye 2 2 3 3 5 22 2 3 5 Drops 6 6 6 6 8 5 5 6 7 8 3 3 5 8 8 3 3 5 8 8 4 5 5 6 6 4 5 6 66 1 1 1 2 3 1 1 2 3 3 5 8 8 8 8 5 5 7 7 8 8 8 10 10 10 8 9 10 9 10 2 2 35 6 2 2 3 6 6 1 1 1 2 3 1 1 1 2 3 2 2 3 4 5 2 3 3 5 5 3 3 3 6 8 3 3 5 88 3 3 4 4 6 3 3 4 6 6 4 4 7 8 8 3 4 7 8 8 4 4 5 6 7 4 4 6 7 7 1 1 3 5 52 2 3 3 5 1 1 3 3 5 1 1 2 5 5 2 2 3 5 5 2 2 3 5 5 2 2 5 6 6 2 2 5 6 6 11 1 2 3 1 1 1 2 3 SUM 58 62 84 107 123 57 61 86 114 123 AVERAGE 2.9 3.14.2 5.35 6.15 2.85 3.05 4.3 5.7 6.15 Placebo 6 6 6 6 6 6 6 6 6 6 Eye 4 55 5 5 4 5 5 5 5 Drops 4 5 5 5 5 4 5 5 5 5 8 8 8 8 8 8 8 8 8 8 4 5 5 5 54 5 5 5 5 6 6 6 6 6 6 6 6 6 6 5 5 5 5 5 5 5 5 5 5 2 3 3 3 3 3 3 3 3 3 88 8 8 8 8 8 8 8 8 7 8 8 8 8 7 8 8 8 8 6 6 6 6 6 6 6 6 6 6 8 8 8 8 8 8 88 8 8 8 8 8 8 8 8 8 8 8 8 6 6 6 6 6 5 6 6 6 6 6 6 6 6 6 5 6 6 6 6 5 5 55 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 3 5 5 5 5 3 5 5 5 5 10 10 10 10 10 1010 10 10 10 2 3 3 3 3 2 3 3 3 3 SUM 113 122 122 122 122 113 122 122 122122 AVERAGE 5.65 6.1 6.1 6.1 6.1 5.65 6.1 6.1 6.1 6.1 Averages Day 7 1hr = 2 hr = 4 hr = 8 hr = 10 hr = Near Near Near Near Near AverageAverage Average Average Average VA (J) VA (J) VA (J) VA (J) VA (J) NearNear Near Near Near 1 hr 2 hr 4 hr 8 hr 10 hr VA (J) VA (J) VA (J) VA(J) VA (J) Placebo 2 3 5 8 8 2.57 3.29 5.14 8 8 Eye 2 2 2 3 5 2 2 2.14 35 Drops 5 6 6 7 8 5.29 5.57 5.86 6.43 8 3 3 5 8 8 3 2.86 5 8 8 4 5 5 6 63.86 5 5.14 5.57 6 1 1 3 3 3 1 1 1.57 2.14 2.86 5 5 7 8 8 5.14 5.71 7.437.86 8.29 8 8 9 9 10 8 8.14 9.86 9.71 10 2 2 3 6 6 2 2.29 3.57 5.29 6 11 1 2 3 1 1 1 2 3 2 3 3 5 5 2.14 2.43 3 4.43 5 3 3 6 8 8 3 3 5 6.57 8 33 4 6 6 3.29 3.71 4.29 5.57 6 3 4 6 7 8 3.71 4 5.86 7.71 8 4 4 7 7 74.57 4.57 6.14 6.86 7 1 2 3 5 5 1.29 1.57 2.71 4.14 5 1 1 3 5 5 1 1 2.433.57 5 2 2 3 5 5 2 2 3.29 4.71 5 2 2 5 6 6 2 2 5 6 6 1 1 1 2 3 1 1 12.29 3 SUM 55 61 87 116 123 AVERAGE 17.5 3.05 4.35 5.8 6.15 2.89 3.114.27 5.49 6.16 Placebo 6 6 6 6 6 6 6 6 6 6 Eye 4 5 5 5 5 4.57 5 5 5 5Drops 4 5 5 5 5 4 5 5 5 5 8 8 8 8 8 7.86 8 8 8 8.14 4 5 5 5 5 4 5 5 5 56 6 6 6 6 6 6 6 6 6 5 5 5 5 5 5 5 5 5 5 3 3 3 3 3 2.43 3 3 3 3 8 8 8 8 88 8 8 8 8 7 8 8 8 8 7.29 8 8 8 8 6 6 6 6 6 5.86 6 6 6 6 8 8 8 8 8 7.71 88 8 8 8 8 8 8 8 8 8 8 8 8 6 6 6 6 6 5.29 5.86 6 6 6 6 6 6 6 6 5.71 6 6 66 5 5 5 5 5 5 5 5 5 5 6 6 6 6 6 6 6 6 6 6 3 5 5 5 5 3 4.71 5 5 5 10 1010 10 10 10 10 10 10 10 3 3 3 3 3 2.14 3 3 3 3 SUM 116 122 122 122 122AVERAGE 5.8 6.1 6.1 6.1 6.1 5.69 6.08 6.1 6.1 6.11

1. A method for ameliorating or reducing presbyopia of a patient havingan eye, comprising administering to said eye an ophthalmic preparationcomprising a therapeutically effective amount of carbachol, orpharmaceutically acceptable salts thereof, and brimonidine, orpharmaceutically acceptable salts thereof.
 2. The method of claim 1,wherein carbachol is present in the preparation in an amount of 1.5-5%.3. The method of claim 1, wherein carbachol is present in thepreparation in an amount of 2.25-3.5%.
 4. The method of claim 1, whereinbrimonidine is present in the preparation in an amount of 0.05-0.3%. 5.A method of producing ocular miosis in a subject which comprisesadministering to the subject an amount of an ophthalmic preparationcomprising a therapeutically effective amount of carbachol, orpharmaceutically acceptable salts thereof, and brimonidine, orpharmaceutically acceptable salts thereof, effective to produce ocularmiosis.
 6. The method of claim 5, wherein carbachol is present in thepreparation in an amount of 1.5-5%.
 7. The method of claim 5, whereincarbachol is present in the preparation in an amount of 2.25-3.5%. 8.The method of claim 5, wherein brimonidine is present in the preparationin an amount of 0.05-0.3%.
 9. A method for ameliorating or reducingpresbyopia of a patient, comprising administering to one eye of thepatient a therapeutically effective amount of an ophthalmic preparationcomprising a therapeutically effective amount of carbachol, orpharmaceutically acceptable salts thereof, and brimonidine, orpharmaceutically acceptable salts thereof.
 10. The method of claim 9,wherein carbachol is present in the preparation in an amount of 1.5-5%.11. The method of claim 9, wherein carbachol is present in thepreparation in an amount of 2.25-3.5%.
 12. The method of claim 9,wherein brimonidine is present in the preparation in an amount of0.05-0.3%.
 13. A method of ameliorating, reducing or eliminating dimnessof vision of a patient having an eye comprising administering to saideye a therapeutically effective amount of an ophthalmic preparationcomprising a therapeutically effective amount of carbachol, orpharmaceutically acceptable salts thereof, and brimonidine, orpharmaceutically acceptable salts thereof.
 14. The method of claim 13,wherein carbachol is present in the preparation in an amount of 1.5-5%.15. The method of claim 13, wherein carbachol is present in thepreparation in an amount of 2.25-3.5%.
 16. The method of claim 13,wherein brimonidine is present in the preparation in an amount of0.05-0.3%.
 17. A method of improving focus and/or correcting refractiveerrors of a patient having an eye comprising administering to said eye atherapeutically effective amount of an ophthalmic preparation comprisinga therapeutically effective amount of carbachol, or pharmaceuticallyacceptable salts thereof, and brimonidine, or pharmaceuticallyacceptable salts thereof.
 18. The method of claim 17, wherein carbacholis present in the preparation in an amount of 1.5-5%.
 19. The method ofclaim 17, wherein carbachol is present in the preparation in an amountof 2.25-3.5%.
 20. The method of claim 17, wherein brimonidine is presentin the preparation in an amount of 0.05-0.3%.
 21. A method of treatingpresbyopia in a patient in need of treatment thereof comprisingadministering an effective amount of an ophthalmic preparationcomprising a therapeutically effective amount of carbachol, orpharmaceutically acceptable salts thereof, and brimonidine to a singleeye of a patient thereby leaving the other eye untreated.
 22. The methodof claim 21, wherein carbachol is present in the preparation in anamount of 1.5-5%.
 23. The method of claim 21, wherein carbachol ispresent in the preparation in an amount of 2.25-3.5%.
 24. The method ofclaim 21, wherein brimonidine is present in the preparation in an amountof 0.05-0.3%.